Lambertini M, et al. - In the Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization (BIG 2-06) phase 3 trial, researchers assessed 2,862 premenopausal females for treatment-related amenorrhea (TRA) rates and the impacts of TRA on disease-free survival (DFS) and overall survival (OS) in those with hormone receptor–positive and –negative tumors. They noticed statistically significantly better DFS and OS for hormone receptor-positive patients in TRA cohort vs the no TRA cohort, while in hormone receptor–negative patients, there was no difference. They observed no link between TRA rate and type of anti-HER2 treatment. Overall, TRA was found in correlation with significant survival gains in premenopausal hormone receptor–positive/HER2-positive early breast cancer outpatients.